» Articles » PMID: 30442661

Quantitation of Class IA PI3Ks in Mice Reveals P110-free-p85s and Isoform-selective Subunit Associations and Recruitment to Receptors

Overview
Specialty Science
Date 2018 Nov 17
PMID 30442661
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Class IA PI3Ks have many roles in health and disease. The rules that govern intersubunit and receptor associations, however, remain unclear. We engineered mouse lines in which individual endogenous class IA PI3K subunits were C-terminally tagged with 17aa that could be biotinylated in vivo. Using these tools we quantified PI3K subunits in streptavidin or PDGFR pull-downs and cell lysates. This revealed that p85α and β bound equivalently to p110α or p110β but p85α bound preferentially to p110δ. p85s were found in molar-excess over p110s in a number of contexts including MEFs (p85β, 20%) and liver (p85α, 30%). In serum-starved MEFs, p110-free-p85s were preferentially, compared with heterodimeric p85s, bound to PDGFRs, consistent with in vitro assays that demonstrated they bound PDGFR-based tyrosine-phosphorylated peptides with higher affinity and co-operativity; suggesting they may act to tune a PI3K activation threshold. p110α-heterodimers were recruited 5-6× more efficiently than p110β-heterodimers to activated PDGFRs in MEFs or to PDGFR-based tyrosine-phosphorylated peptides in MEF-lysates. This suggests that PI3Kα has a higher affinity for relevant tyrosine-phosphorylated motifs than PI3Kβ. Nevertheless, PI3Kβ contributes substantially to acute PDGF-stimulation of PIP and PKB in MEFs because it is synergistically, and possibly sequentially, activated by receptor-recruitment and small GTPases (Rac/CDC42) via its RBD, whereas parallel activation of PI3Kα is independent of its RBD. These results begin to provide molecular clarity to the rules of engagement between class IA PI3K subunits in vivo and past work describing "excess p85," p85α as a tumor suppressor, and differential receptor activation of PI3Kα and PI3Kβ.

Citing Articles

Investigating the Interplay Between the Nrf2/Keap1/HO-1/SIRT-1 Pathway and the p75NTR/PI3K/Akt/MAPK Cascade in Neurological Disorders: Mechanistic Insights and Therapeutic Innovations.

Mukherjee R, Rana R, Mehan S, Khan Z, Gupta G, Narula A Mol Neurobiol. 2025; .

PMID: 39920438 DOI: 10.1007/s12035-025-04725-8.


Paradoxical dominant negative activity of an immunodeficiency-associated activating variant.

Tomlinson P, Knox R, Perisic O, Su H, Brierley G, Williams R Elife. 2025; 13.

PMID: 39835783 PMC: 11750134. DOI: 10.7554/eLife.94420.


Molecular Basis of Oncogenic PI3K Proteins.

Sheng Z, Beck P, Gabby M, Habte-Mariam S, Mitkos K Cancers (Basel). 2025; 17(1).

PMID: 39796708 PMC: 11720314. DOI: 10.3390/cancers17010077.


Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.

Hashemi M, Abolghasemi Fard A, Pakshad B, Asheghabadi P, Hosseinkhani A, Hosseini A Noncoding RNA Res. 2024; 11:1-21.

PMID: 39720352 PMC: 11665378. DOI: 10.1016/j.ncrna.2024.11.006.


Oncogenic PIK3CA corrupts growth factor signaling specificity.

Madsen R, Le Marois A, Mruk O, Voliotis M, Yin S, Sufi J Mol Syst Biol. 2024; 21(2):126-157.

PMID: 39706867 PMC: 11791070. DOI: 10.1038/s44320-024-00078-x.


References
1.
Thorpe L, Yuzugullu H, Zhao J . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2014; 15(1):7-24. PMC: 4384662. DOI: 10.1038/nrc3860. View

2.
Oak J, Chen J, Peralta R, Deane J, Fruman D . The p85beta regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. Autoimmunity. 2009; 42(5):447-58. PMC: 2804088. DOI: 10.1080/08916930902911746. View

3.
Fruman D, Snapper S, Yballe C, Davidson L, Yu J, Alt F . Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science. 1999; 283(5400):393-7. DOI: 10.1126/science.283.5400.393. View

4.
Zhao J, Cheng H, Jia S, Wang L, Gjoerup O, Mikami A . The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A. 2006; 103(44):16296-300. PMC: 1637576. DOI: 10.1073/pnas.0607899103. View

5.
Clark J, Anderson K, Juvin V, Smith T, Karpe F, Wakelam M . Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat Methods. 2011; 8(3):267-72. PMC: 3460242. DOI: 10.1038/nmeth.1564. View